KLOW peptide: four compounds, one vial, zero studies of the combination

KLOW peptide is four research compounds co-lyophilized into one vial. Three of them are the GLOW blend. The fourth is KPV. No study has ever given the four together, in any species.

What is in a KLOW peptide vial?

“KLOW” is an acronym vendors assembled from the four ingredients, not a name any journal uses. It refers to a single lyophilized cake containing four research peptides. The configuration the market has settled on is 80 mg total:

• GHK-Cu, 50 mg — the copper(II) complex of an endogenous tripeptide, and the reason the reconstituted vial turns blue. Full monograph: GHK-Cu complete guide.
• BPC-157, 10 mg — a synthetic 15-amino-acid peptide derived from a sequence in human gastric juice. Full monograph: BPC-157 complete guide.
• TB-500, 10 mg — the research-market name for thymosin beta-4 or its active fragment. Full monograph: TB-500 complete guide.
• KPV, 10 mg — the C-terminal tripeptide of alpha-MSH, and the only ingredient KLOW does not share with GLOW. Full monograph: KPV complete guide.

Read those milligrams again, because the split is the most important fact on this page. GHK-Cu is 62.5% of the vial by mass. The other three share the remaining 37.5% equally. Whatever else KLOW is, it is mostly a GHK-Cu product.

Not every vendor uses that split. The 80 mg total is close to universal, and 50/10/10/10 is the common configuration, but the ratio is a market convention rather than a specification. Check the label rather than assuming it.

KLOW is GLOW plus KPV

The clearest way to understand KLOW is by subtraction. Take the GLOW blend — BPC-157, TB-500 and GHK-Cu at 10/10/50, for 70 mg — and add 10 mg of KPV. That is KLOW. The letter K is the whole difference.

KPV is the C-terminal fragment of alpha-melanocyte-stimulating hormone, the part of the parent hormone that keeps the anti-inflammatory activity and drops the pigmentation. The rationale for adding it is that the other three address repair, and KPV addresses the inflammation running alongside it. That is a reasonable hypothesis. It is also the entire case, and nobody has tested it. We compare the two vials directly in KLOW vs GLOW.

What does the KLOW peptide do?

It does four separate things, because there is no shared mechanism to describe. Each ingredient acts on a different pathway, and the vial does not create a fifth one.

GHK-Cu delivers copper to proteins involved in collagen synthesis and antioxidant defense, and Pickart’s gene-expression work reports it shifting the expression of a large fraction of human genes in culture. Serum GHK falls with age, which is where the anti-aging framing comes from. See the collagen mechanism.

BPC-157 is described as acting through VEGFR2 activation with downstream nitric-oxide signaling, recruiting fibroblasts into injury sites. That mechanism story is well developed and almost entirely rodent. See the VEGFR2 pathway.

TB-500 binds monomeric G-actin at a 1:1 ratio, which is how a cell controls the actin dynamics it uses to crawl into a wound. This is the cleanest molecular biology of the four. See the actin-binding mechanism.

KPV suppresses NF-kappaB signaling in intestinal epithelial and immune cells, and the colitis work shows it entering those cells through the PepT1 transporter rather than through a melanocortin receptor. See the KPV mechanism.

What each of the four has behind it

The four are not equally evidenced, and the gap between them is wide. Here is the record for each, at the level of what has actually been published in humans. Each marketing claim traced back to the ingredient it came from is the subject of KLOW peptide benefits.

A 2025 systematic review in the orthopaedic sports-medicine literature counted 36 studies of BPC-157 meeting its criteria: 35 preclinical and 1 human. That single human entry is a retrospective knee-pain case series of 17 patients with no control arm.

KPV’s record is thinner still and cleaner to describe. Two 2008 papers established the anti-inflammatory signal in murine colitis models, one of them showing PepT1-mediated uptake at nanomolar concentrations in culture. Nothing has followed in humans. We cover the studies in KPV in ulcerative colitis models.

GHK-Cu is the best evidenced of the four, and it is evidenced for a route this vial does not use. The controlled human work is topical, measured as a formulation percentage. Injected GHK-Cu has no published randomized trial. That distinction is the subject of injectable vs topical GHK-Cu.

KLOW Blend

GHK-Cu + BPC-157 + TB-500 + KPV80 mg vialResearch use only

The four-component blend described here, co-lyophilized in one vial, with a third-party certificate of analysis matched to the lot.

Shop KLOW blend

How long should you be on KLOW peptide?

No study defines a duration, because no study has given the blend at all. Schedules circulating online were reconstructed from the constituents, and two of the four constituents have no human schedule to reconstruct from.

There is a second reason duration is not a free variable here, and it is arithmetic rather than pharmacology. Fifty milligrams of GHK-Cu carries roughly 7.9 mg of elemental copper. The tolerable upper intake level for copper in adults is 10 mg per day from all sources. A vial of KLOW is therefore close to a full day’s ceiling of copper in one container, and how fast you go through it is a copper question before it is a peptide question. We work through this in KLOW peptide dosage.

Two of the four are also prohibited in sport. BPC-157 has been listed by WADA under S0 since January 2022, and thymosin beta-4 falls under S2. A tested athlete is looking at a vial with two banned substances in it.

How much does KLOW peptide cost, and what are you paying for?

Price the vial per milligram and the answer changes shape. At 80 mg total, 50 mg of what you buy is GHK-Cu. If a KLOW vial costs more than a GHK-Cu vial plus a KPV vial, you are paying a premium for co-lyophilization, not for more material.

That premium buys one real thing: the ratio is fixed for you and you mix one vial instead of four. It also costs one real thing, which is that you can never move a single component. More on that trade in the sourcing guide below.

All four are also sold separately, which is how most of this market works, and three of them are sold together as GLOW. So the same composition can be assembled from two or four vials instead of bought pre-mixed. Whether that is cheaper depends entirely on the vendor and the day, and it is worth checking rather than assuming. Where to buy KLOW works through both routes.

What to check before buying a four-way blend

A blend makes the certificate of analysis harder to read, and the difficulty scales with the number of components. Four is the most this market usually asks of a document.

• Per-component quantitation, not a single purity number. “99% pure” on a four-compound vial does not tell you the split. Ask for weight percent per component.
• Identity for all four. Mass spectrometry should confirm four masses. Read how to read a peptide COA before you open one.
• Which TB-500. The name covers both full-length thymosin beta-4 and its active fragment, and suppliers do not consistently declare which. A purity figure does not settle it.
• Lot match. The document should carry the lot number on the vial in your hand, not a representative batch. Storage matters too — see peptide storage temperature.

What people usually want next is results, and that question has its own page: KLOW peptide before and after audits the human record ingredient by ingredient.

The blue color is worth a note, because it gets read as a quality signal. It is not one. Copper(II) complexes are blue, so a KLOW solution turning blue tells you copper is present and nothing else about purity or ratio.

KLOW Blend

Batch-matched COAHPLC + mass specResearch use only

Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.

Learn more

Frequently asked questions